Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq:XFOR) reported financial results for the quarter ended June 30, 2026 and detailed progress across its rare hematology portfolio. Revenue was $8.8 million for the quarter and $11.5 million for the first half of 2026, including $2.4 million and $4.8 million in net U.S. XOLREMDI® product sales and $6.4 million and $6.7 million in license and other revenue, largely from its Norgine agreement.
Research and development expenses declined to $15.1 million in the quarter, while general and administrative expenses fell to $8.5 million. Net loss narrowed to $16.2 million, or $(0.13) per share, for the quarter. Cash, cash equivalents, and marketable securities totaled approximately $208 million at June 30, 2026, which the company said provides a cash runway into 2029. Operationally, X4 transitioned management of its global Phase 3 4WARD chronic neutropenia trial to a premier CRO, continued enrolling patients at over 110 sites, and expects an FDA meeting update and enrollment completion timing by the end of the third quarter of 2026. The European Commission granted marketing authorization for XOLREMDI for WHIM syndrome, with commercialization in Europe led by partner Norgine and up to an additional €221 million in potential milestones plus escalating double-digit royalties.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement equity awards to new employees effective July 31, 2026 under its 2019 Inducement Equity Incentive Plan. The awards comprise stock options to purchase an aggregate of 12,000 shares of common stock, granted pursuant to Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.
The options have a ten-year term and an exercise price of $3.98 per share, equal to X4’s closing stock price on July 31, 2026. Each option vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, subject to continued employment and the terms of the 2019 Inducement Plan and related award agreements. X4 focuses on rare hematology diseases and has developed mavorixafor, approved as XOLREMDI for WHIM syndrome, and is running the global Phase 3 4WARD trial in chronic neutropenic disorders.
X4 Pharmaceuticals (Nasdaq:XFOR) granted stock options as inducement awards to new employees under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026.
The awards cover 750,000 shares at a $4.03 exercise price, with a ten-year term and four-year vesting schedule.
X4 Pharmaceuticals (Nasdaq:XFOR) appointed Kelly Gold to its Board of Directors effective July 1, 2026. She will serve as an independent director and member of the Audit Committee. Her background spans public company CFO experience, capital markets, biotech finance, and engineering and biochemistry training.
According to X4 Pharmaceuticals, the company aims to leverage her expertise as it advances mavorixafor toward potential approval and commercialization in rare hematology and rare disease settings.
X4 Pharmaceuticals (Nasdaq:XFOR) granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan, effective May 29, 2026. The awards cover 160,000 shares at an exercise price of $4.31 per share, with a ten-year term and four-year vesting schedule.
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET. A live and archived webcast of the presentation will be available via the Investors section of the company’s website.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: EU marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome, continued enrollment progress in the global 4WARD Phase 3 chronic neutropenia trial, and a $233.7M cash balance providing runway through 2028. The Norgine license could yield up to €226M in milestones plus escalating royalties; Q1 revenue was $2.7M versus $28.8M prior year, and net loss was $(20.2)M.
X4 Pharmaceuticals (Nasdaq: XFOR) announced European Commission marketing authorization for XOLREMDI (mavorixafor) to treat WHIM syndrome in patients 12 years and older, granted under exceptional circumstances. The authorization follows a positive CHMP opinion and is supported by the pivotal Phase 3 4WHIM trial in 31 patients.
European commercialization will be led by partner Norgine under a 2025 license and supply agreement with up to €226 million in contingent payments plus escalating royalties; X4 will manufacture and supply the medicine.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective March 31, 2026, granting options to purchase an aggregate of 32,000 shares under its 2019 Inducement Equity Incentive Plan.
The options carry a 10-year term, an exercise price of $4.13 (closing price on March 31, 2026) and a four-year vesting schedule (25% after 12 months, then monthly over 36 months).
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q4 and full‑year 2025 results and a corporate update on March 17, 2026. Key items: 4WARD Phase 3 enrollment on track to complete in Q3 2026, a positive CHMP opinion for mavorixafor in WHIM syndrome, and a $253.0M cash position that management says funds operations through 2028.
Financials: 2025 product sales $6.5M, license revenue $28.6M, operating loss $86.9M, and net loss $79.2M for the year ended December 31, 2025.